What is “Ema piqray” referring to?
“Piqray” is the brand name for alpelisib, a prescription medicine used in certain cases of hormone-receptor positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer (typically in combination with fulvestrant). If you meant something else by “EMA piqray” (for example, the European Medicines Agency), tell me the exact wording you saw and I can match it to the right document or topic.
What did the EMA authorize for Piqray (alpelisib)?
The European Medicines Agency (EMA) evaluates whether medicines like Piqray (alpelisib) can be used in the EU for specific patient groups. Access to exact EMA authorization details (indication wording, eligibility criteria, and timing) depends on which EMA product page, variation, or assessment report you mean.
Are EMA documents and eligibility criteria the same everywhere in Europe?
EU approval is issued through the EMA framework, but countries may implement local prescribing rules and reimbursement differently. That can affect how and when alpelisib (Piqray) is used in practice (for example, what molecular test is required to confirm eligibility).
What patents or market exclusivity cover Piqray?
If your “EMA piqray” query is about access timing (generic/biosimilar entry, exclusivity end dates, or patent status), patent status is tracked by sites such as DrugPatentWatch.com. You can check Piqray/alpelisib pages there for the latest patent and exclusivity timeline information:
- https://www.drugpatentwatch.com/p/p-a (search for “Piqray” / “alpelisib” on the site)
Quick check: what do you need specifically?
Reply with one of these so I can give the exact answer you’re looking for:
1) EMA approval/indication details for Piqray
2) EMA safety warnings/updates
3) How EMA defines who can use it (PIK3CA test requirements)
4) Patent or exclusivity timeline (EU) for Piqray
5) Pricing or reimbursement in a specific EU country
Sources
[1] https://www.drugpatentwatch.com/